Press Release

March 12, 2019
Verastem Oncology to Present at Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--Mar. 12, 2019-- Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that the Company will present at the following upcoming investor conferences:

  • The 31st Annual ROTH Conference on Tuesday, March 19, 2019 at 12:00pm PDT in Dana Point, CA, USA
  • The Oppenheimer 29th Annual Healthcare Conference on Tuesday, March 19, 2019 at 11:30am EDT in New York City, NY, USA

A live webcast of these presentations will be available on the investors section of the Company’s website at www.verastem.com. An archived presentation will be available for 90 days.

About Verastem Oncology

Verastem Oncology (Nasdaq:VSTM) is a commercial biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. We are driven by the strength, tenacity and courage of those battling cancer – single-minded in our resolve to deliver new therapies that not only keep cancer at bay, but improve the lives of patients diagnosed with cancer. Because for us, it’s personal.

Our first FDA approved product is now available for the treatment of patients with certain types of indolent non-Hodgkin’s lymphoma (iNHL). Our pipeline comprises product candidates that seek to treat cancer by modulating the local tumor microenvironment. For more information, please visit www.verastem.com.

Source: Verastem, Inc.

Verastem Oncology:
Erin Cox
Senior Director, Investor Relations and Corporate Communications
+1 781-469-1553
ecox@verastem.com

Investors:
Joseph Rayne
Argot Partners
+1 617-340-6075
joseph@argotpartners.com